SinoMab BioScience Limited — Regulatory Filings 2021

Jan 15, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 43] intentionally omitted <==

==> picture [29 x 43] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

VOLUNTARY ANNOUNCEMENT FIRST HEALTHY SUBJECT DOSED IN A PHASE I CLINICAL TRIAL OF SN1011 IN CHINA

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有 限公司) (the “ Company ”, together with its subsidiaries, the “ Group ”) on 14 November 2019, 29 January 2020, 29 June 2020 and 1 September 2020 in relation to the latest research and development progress of one of the Group’s key products, SN1011.

The board (the “ Board ”) of directors (“ Directors ”) of the Company is pleased to announce that the first healthy subject has been successfully dosed in a Phase I clinical trial of SN1011, an innovative third generation Bruton’s tyrosine kinase (“ BTK ”) inhibitor, in Shanghai, China.

The Phase I clinical trial of SN1011 conducted in China is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in treatment for autoimmune diseases.

SN1011 is the Company’s third generation, covalent reversible BTK inhibitor designed for higher selectivity and superior efficacy for the long-term treatment of systemic lupus erythematosus, rheumatoid arthritis, pemphigus, multiple sclerosis and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, selectivity and affinity.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Director

Hong Kong, 15 January 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.